Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rearranged during transfection receptor (RET)
- Target
- RET
- Molecular classification
- Receptor, Enzyme, Receptor tyrosine kinase, Transmembrane receptor protein tyrosine kinase
01
Overview
The **rearranged during transfection receptor (RET)** is a receptor tyrosine kinase that plays a critical role in signal transduction pathways regulating cell proliferation, differentiation, survival, and migration. Germline and somatic activating mutations or gene fusions involving RET are oncogenic drivers in medullary thyroid carcinoma, papillary thyroid cancer, and other malignancies. RET is the therapeutic target of multiple tyrosine kinase inhibitors, including vandetanib, which selectively inhibits its kinase activity to block tumor cell growth, invasion, and angiogenesis, especially in advanced medullary thyroid cancer.
- Other names
- RET proto-oncogeneProto-oncogene tyrosine-protein kinase receptor RETCD antigen CD221
02
Mechanism of action
Inhibition of RET receptor tyrosine kinase activity; Blockade of downstream signal transduction pathways (e.g., Rho-GTPase/JNK, PI3K, MAPK); Inhibition of tumor growth, angiogenesis, and metastasis through suppression of RET-mediated signals.
03
Biological functions
Signal transductionCell proliferationCell differentiationApoptosis (programmed cell death)Neural crest development
04
Disease associations
CancerMedullary thyroid cancerMultiple endocrine neoplasia type 2Papillary thyroid cancer
05
Safety considerations
QT interval prolongation (risk of torsades de pointes and sudden cardiac death)Diarrhea, nausea, vomitingHypertensionSkin rash, photosensitivityHepatic toxicityTeratogenicity (fetal harm)
06
Interacting drugs
Vandetanib
5 more in the full profile.
07
Biomarkers
RET gene mutations, including RET M918T and C634RRET fusion events (e.g., RET/PTC rearrangements in papillary thyroid cancer)
Beyond the preview
Go deeper on Rearranged during transfection receptor (RET).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rearranged during transfection receptor (RET).